172 related articles for article (PubMed ID: 21603167)
1. Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations.
Khatami F; Larijani B; Nasiri S; Tavangar SM
Int J Mol Cell Med; 2019; 8(Suppl1):19-29. PubMed ID: 32351906
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
3. Suppression of
Shi X; Cheng S; Wang W
Oncol Lett; 2018 Jun; 15(6):9202-9208. PubMed ID: 29805652
[TBL] [Abstract][Full Text] [Related]
4. Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients.
Dehghan R; Hosseinpour Feizi MA; Pouladi N; Babaei E; Montazeri V; Fakhrjoo A; Sedaei A; Azarfam P; Nemati M
Pathol Oncol Res; 2015 Apr; 21(2):449-54. PubMed ID: 25410025
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.
Duman BB; Kara OI; Uğuz A; Ates BT
Contemp Oncol (Pozn); 2014; 18(4):234-40. PubMed ID: 25258580
[TBL] [Abstract][Full Text] [Related]
6. Candidate agents for papillary thyroid cancer identified by gene expression analysis.
Zhu W; Li C; Ai Z
Pathol Oncol Res; 2013 Jul; 19(3):597-604. PubMed ID: 23519608
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.
Urie BK; Russell DS; Kisseberth WC; London CA
BMC Vet Res; 2012 May; 8():67. PubMed ID: 22630170
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in molecular diagnosis of thyroid cancer.
Legakis I; Syrigos K
J Thyroid Res; 2011; 2011():384213. PubMed ID: 21603167
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in molecular biology of thyroid cancer and their clinical implications.
Xing M
Otolaryngol Clin North Am; 2008 Dec; 41(6):1135-46, ix. PubMed ID: 19040974
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
11. Genetic considerations in thyroid cancer.
Patel KN; Singh B
Cancer Control; 2006 Apr; 13(2):111-8. PubMed ID: 16735985
[TBL] [Abstract][Full Text] [Related]
12. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Hou P; Ji M; Xing M
Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
[TBL] [Abstract][Full Text] [Related]
13. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.
Hou P; Bojdani E; Xing M
J Clin Endocrinol Metab; 2010 Feb; 95(2):820-8. PubMed ID: 20008023
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
